Aspirin for Primary Prevention of Myocardial Infarction: An Evidence Based Clinical Inquiry

Main Article Content

Brooklyn Rain Nemetchek


Evidence is evaluated to determine whether low dose aspirin (81mg) for primary prevention in patients aged 50-65 with no history of cardiovascular disease decreases the incidence of myocardial infarction. Ten studiesgiving relevant clinical evidence are identified and evaluated, with each gender looked at in isolation.The preliminary evidence of this paper suggests that aspirin for the primary prevention of myocardial infarction is not suitable for women aged 50-65, while it does hold benefits for males of the same age range (Howard, 2014). However, the evidence is not unanimous, and more research is needed before recommending aspirin for primary prevention in all low-risk individuals. In relation to aspirin for primary prevention of myocardial infarction,short- and long-term recommendations for nursing practice are developed and discussed, demonstrating the significant role the nurse plays in education, helping each patient to assess individual risks and benefits, and advising patients to consult their physician before self-medicating (Howard, 2014).